<info type="GeneOrGeneProduct">STAT4</info> gene <info type="SequenceVariant">single-nucleotide polymorphism</info> to <info type="DiseaseOrPhenotypicFeature">systemic lupus erythematosus</info> in the <info type="OrganismTaxon">Polish</info> population.

The <info type="GeneOrGeneProduct">STAT4</info> has been found to be a susceptible gene in the development of <info type="DiseaseOrPhenotypicFeature">systemic lupus erythematosus</info> (<info type="DiseaseOrPhenotypicFeature">SLE</info>) in various populations. There are evident population differences in the context of clinical manifestations of <info type="DiseaseOrPhenotypicFeature">SLE</info>, therefore we investigated the prevalence of the <info type="GeneOrGeneProduct">STAT4</info> <info type="SequenceVariant">G &gt; C (rs7582694)</info> polymorphism in patients with <info type="DiseaseOrPhenotypicFeature">SLE</info> (n = 253) and controls (n = 521) in a sample of the <info type="OrganismTaxon">Polish</info> population. We found that patients with the <info type="GeneOrGeneProduct">STAT4</info> <info type="SequenceVariant">C/G</info> and <info type="SequenceVariant">CC</info> genotypes exhibited a 1.583-fold increased risk of <info type="DiseaseOrPhenotypicFeature">SLE</info> incidence (95 % CI = 1.168-2.145, p = 0.003), with OR for the <info type="SequenceVariant">C/C</info> versus <info type="SequenceVariant">C/G</info> and <info type="SequenceVariant">G/G</info> genotypes was 1.967 (95 % CI = 1.152-3.358, p = 0.0119). The OR for the <info type="GeneOrGeneProduct">STAT4</info> <info type="SequenceVariant">C</info> allele frequency showed a 1.539-fold increased risk of <info type="DiseaseOrPhenotypicFeature">SLE</info> (95 % CI = 1.209-1.959, p = 0.0004). We also observed an increased frequency of <info type="GeneOrGeneProduct">STAT4</info> <info type="SequenceVariant">C/C</info> and <info type="SequenceVariant">C/G</info> genotypes in <info type="DiseaseOrPhenotypicFeature">SLE</info> patients with <info type="DiseaseOrPhenotypicFeature">renal symptoms</info> OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in <info type="DiseaseOrPhenotypicFeature">SLE</info> patients with <info type="DiseaseOrPhenotypicFeature">neurologic manifestations</info> OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272). Moreover, we found a contribution of <info type="GeneOrGeneProduct">STAT4</info> <info type="SequenceVariant">C/C</info> and <info type="SequenceVariant">C/G</info> genotypes to the presence of the <info type="ChemicalEntity">anti-snRNP Ab</info> OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the <info type="ChemicalEntity">anti-Scl-70 Ab</info> OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476). Our studies confirmed an association of the <info type="GeneOrGeneProduct">STAT4</info> <info type="SequenceVariant">C (rs7582694)</info> variant with the development of <info type="DiseaseOrPhenotypicFeature">SLE</info> and occurrence of some clinical manifestations of the disease.